Stockscreener 앱 받기
21.31
0.98%
-0.21
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
United States Neuromuscular Disease Therapeutics Market - openPR.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2025 - BioSpace
Sarepta Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Voya Investment Management LLC Trims Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Reach - openPR.com
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny - MSN
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 - openPR.com
Japan Gene Therapy Market is expected to reach US$ 904.94 Million - openPR.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys - MSN
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Assenagon Asset Management S.A. Sells 838,457 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-Hours - MSN
Sarepta Therapeutics Earnings Notes - Trefis
Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Tuesday? (CORRECTED) - Benzinga
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 3.5%Here's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Sarepta to refinance $291M of existing notes due 2027 - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Reach Out - ACCESS Newswire
Aug Intraday: Will Sarepta Therapeutics Inc stock split attract more investorsOil Prices & Verified Momentum Stock Watchlist - moha.gov.vn
Have Insiders Sold Sarepta Therapeutics Shares Recently? - simplywall.st
How Sarepta Therapeutics Inc. stock compares to industry benchmarksPortfolio Gains Report & Real-Time Market Trend Scan - ulpravda.ru
Sarepta Therapeutics exchanges $291.4 million in convertible notes for new securities By Investing.com - Investing.com Nigeria
Sarepta Therapeutics Extends Debt Maturities with New Notes - TipRanks
Sarepta Therapeutics exchanges $291.4 million in convertible notes for new securities - Investing.com
Sarepta Therapeutics Signs Multiple Financing Agreements - TradingView — Track All Markets
Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stockJuly 2025 Update & High Conviction Trade Alerts - Улправда
What Does the Market Think About Sarepta Therapeutics Inc? - Benzinga
Is Sarepta Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Patterns & Reliable Price Action Trade Plans - DonanımHaber
Sarepta Therapeutics (NASDAQ:SRPT) COO Ian Michael Estepan Sells 13,187 Shares - MarketBeat
Insider Sale: Chief Operating Officer of $SRPT Sells 13,187 Shares - Quiver Quantitative
Sarepta Therapeutics COO Sells Shares - TradingView — Track All Markets
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect - ACCESS Newswire
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Finviz
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Yahoo Finance
Will FDA Liver Warning and Newborn Screening Expansion Change Sarepta Therapeutics' (SRPT) Risk‑Reward Narrative? - Sahm
Will Sarepta Therapeutics Inc. stock maintain momentum in 2025Exit Point & Technical Buy Zone Confirmations - Улправда
Sarepta Therapeutics Inc Stock Analysis and ForecastRisk-Reward Ratio Analysis & Low Entry Investment Portfolio - earlytimes.in
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - Stock Traders Daily
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sarepta Therapeutics Applauds Addition of Duchenne Muscular Dystrophy to the U.S. Recommended Uniform Screening Panel (RUSP) - Sarepta Therapeutics
Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Argenx Se (ARGX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
The Worst Biopharma CEO of 2025 made decisions with tragic consequences - statnews.com
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Sarepta Therapeutics (SRPT) Rises as HHS Expands Newborn Screeni - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.3%Still a Buy? - MarketBeat
Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025 - ts2.tech
Why Sarepta Therapeutics Stock is Gaining Attention - TipRanks
Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings - Seeking Alpha
Sarepta’s Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences’ (SLDB) SGT-003 in Duchenne Therapy - Yahoo Finance
A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. - CBS News
683 Capital Management LLC Grows Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap DownHere's What Happened - MarketBeat
0.57%
자본화:
|
볼륨(24시간):